알테오젠의 진격: 플랫폼 기술의 확장과 기업 구조 개편이라는 승부수 > K-wave Trends

Alteogen recently demonstrated the potential of its self-developed recombinant human hyaluronidase, 'ALT-B4', at the 'World ADC Summit' held in Seoul. ADC treatments, which have historically relied on intravenous (IV) administration, have suffered from chronic issues such as reduced patient convenience and increased hospital stay times. Through preclinical studies on mini-pigs, Alteogen confirmed that when ALT-B4 is used in combination for subcutaneous (SC) injection, drug absorption speed increases and bioavailability is significantly improved. This is evaluated as an innovative attempt that could change the paradigm of cancer treatment by optimizing the pharmacokinetic indicators of therapeutics, going beyond a mere change in administration method.

The most notable aspect of these preclinical results is the groundbreaking improvement in the safety profile. Common side effects of anti-cancer drug administration, such as skin toxicity and hematological abnormalities, were noticeably mitigated in the group treated with the ALT-B4 combination. According to experimental data, neutropenia occurred less frequently compared to the IV group, and toxicity indicators such as elevated triglycerides or liver enzyme levels were also significantly improved. This demonstrates the possibility of solving the chronic side-effect issues of ADC treatments through platform technology, and it is expected to become a key driver for expanding collaboration with global partners like Daiichi Sankyo.

Alongside technological success, Alteogen has made strategic decisions to improve its corporate structure. The recent decision to absorb and merge its subsidiary, Alteogen Biologics, is a preemptive measure to respond to the external environment of tightened government regulations on dual listings. When the initial plan to secure R&D funding through the subsidiary's IPO was blocked by regulatory hurdles, the company pivoted toward integrating the organization and maximizing efficiency through a merger. The high approval rate from external investors proves that this management decision has gained the trust of the capital market, and a reasonable valuation during the merger ratio calculation process will be the final gateway to enhancing corporate value.

Market reactions are sending positive signals regarding these technological and strategic moves. By receiving a notice of intent to grant a patent related to ALT-B4 from the European Patent Office, the company has strengthened its exclusive technological status, and the stock price has recorded a significant upward trend following the announcement of preclinical results, leading the vitality of the KOSDAQ market. This is not a short-term fluctuation based on mere expectations, but signifies that investors share the conviction that Alteogen's platform technology can be a true game-changer in the massive ADC market. As global pharmaceutical companies are already showing interest in ADC subcutaneous formulations, Alteogen's technological edge is highly likely to lead to continuous expansion of partnerships.